NEW YORK (GenomeWeb News) – Cepheid today acquired Actigenics for an undisclosed sum, the company said today.
Cepheid acquired the French company for its microRNA portfolio. Actigenics possesses both therapeutic and diagnostic rights to validated microRNAs. Cepheid plans to out-license therapeutic applications of these microRNAs, the company said in a statement.
The microRNAs may potentially provide the basis for a broad range of proprietary markers for Cepheid in “cancer-specific markers, infection-specific markers, inflammation-specific
markers, and surrogate markers of complex regulatory mechanisms,” the company said.
Cepheid may also develop diagnostic tests associated with the therapeutic applications.
Financial details were not disclosed.